Peter A. Haddad

Peter’s practice focuses on public and private securities offerings. He represents investment banks and high-growth companies in a broad range of capital markets transactions, including initial public offerings (IPOs), follow-on equity offerings, convertible note offerings, high-yield and investment-grade debt offerings, and de-SPAC business combinations, with a focus on the life sciences and technology sectors.

Peter also advises public companies on general corporate and securities matters, including Securities Exchange Act reporting obligations, corporate governance, stock exchange compliance and other strategic transactions.

Peter’s recent representations include advising:

IPOs and de-SPAC business combinations

• The underwriters in StubHub Holdings’ $800 million IPO
• The underwriters in CG Oncology’s $437 million IPO
• The underwriters in HeartFlow’s $364 million IPO
• The underwriters in Apogee Therapeutics’ $345 million IPO
• AIRO Group Holdings in its $69 million IPO
• Infleqtion in its $550 million SPAC merger

Follow-on equity offerings

• The underwriters in Viking Therapeutics’ $632 million follow-on offering
• The underwriters in Crinetics Pharmaceuticals’ $575 million follow-on offering
• Mirati Therapeutics in its $345 million follow-on offering
• CG Oncology in its $257 million follow-on offering
• Kodiak Sciences in its $184 million follow-on offering
• LegalZoom in its $161 million follow-on secondary offering

Investment-grade, high-yield and convertible debt offerings

• Uber Technologies in its $2.25 billion investment grade bond offering
• Uber Technologies in its $1.15 billion exchangeable notes offering
• BioMarin Pharmaceutical in its $850 million high-yield senior notes offering
• Air Lease Corporation in its $700 million medium-term notes offering
• The initial purchasers in Etsy’s $700 million Rule 144A offering of convertible senior notes

Concurrent equity and convertible note offerings

• The underwriters and initial purchasers in Mirion Technologies’ concurrent follow-on offering of $425 million of common stock and Rule 144A offering of $375 million of convertible senior notes
• The underwriters and initial purchasers in Guardant Health’s concurrent follow-on offering of $345 million of common stock and Rule 144A offering of $402.5 million convertible senior notes
• The underwriters in Zenas BioPharma’s concurrent registered follow-on offering of $115 million of common stock and registered offering of $230 million convertible senior notes